The short answer
Oligometastatic cancer means a small, limited number of metastases. Because the disease is confined, local treatments such as targeted radiation or surgery may be used with long-term control in mind.
Oligometastatic describes cancer that has spread, but only to a limited number of sites. It sits between localised disease and widespread metastatic disease.
There is no single agreed definition. Many studies use five or fewer metastases as a working cut-off, a threshold NCI notes was arbitrarily chosen.
The significance is that local treatments aimed at the metastases themselves, such as surgery or stereotactic body radiation, may be added to systemic therapy.
In colorectal cancer with liver-only metastases, roughly 20 percent of people are alive at ten years after surgical removal of the primary tumour and the metastases.
Choose how you want to understand this
The full explanation.
A Middle Category That Many People Never Hear Named
Most people are given one of two pictures: the cancer is localised, or the cancer has spread. Oligometastatic describes a state in between — cancer that has spread, but only to a small number of places.
The prefix oligo- simply means few. The reason it matters is not linguistic. If the disease is genuinely confined to a handful of sites, it may be possible to treat those sites directly, and in some people that produces long-term control or cure rather than only slowing things down.
As researchers quoted by the National Cancer Institute put it, metastasis is a spectrum. Cancers vary in how many deposits they produce and how fast they progress, and putting every metastatic cancer into one category obscures that.
How Few Is Few
There is no single agreed definition, and it is worth knowing that rather than assuming a threshold exists.
Many studies use five or fewer metastases as a working cut-off. NCI notes plainly that this number was arbitrarily decided upon. Other frameworks add constraints on how many organs are involved, or distinguish between metastases present at diagnosis and those appearing later after the original cancer was treated.
In practice the count is only part of the assessment. Where the deposits are, whether they can be safely reached, how quickly they appeared, and how the cancer has behaved on systemic treatment all weigh heavily.
What Changes If the Label Applies
Standard treatment for metastatic cancer is systemic — drug therapy that travels through the whole body. In oligometastatic disease, the possibility opens up of adding local treatment aimed at the metastases themselves:
- Surgery to remove a metastasis, most established for liver deposits from colorectal cancer and for limited lung metastases
- Stereotactic body radiation therapy (SBRT/SABR), which delivers a high, precisely focused dose to a small target over a few sessions
- Other ablative techniques such as radiofrequency or microwave ablation in selected sites
The intent shifts. Rather than controlling disease indefinitely with drugs, the aim may be to eliminate every visible site of cancer.
What the Evidence Shows
The clearest example is colorectal cancer that has spread only to the liver. When the primary tumour and the liver metastases are surgically removed, roughly 20 percent of people are alive at ten years. That is not slowing disease down; for those people it is cure.
Beyond that, the SABR-COMET trial randomly assigned people with a limited number of metastases from various cancers to standard treatment alone or standard treatment plus SBRT to all metastatic sites. Those who received SBRT lived more than a year longer than the control group.
That result is genuinely encouraging and genuinely provisional. The trial was small, the mix of cancer types was not evenly balanced between the groups, and there were three treatment-related deaths. Researchers involved have been careful to say that larger trials should report before practice changes wholesale. SABR-COMET-3 and SABR-COMET-10, along with other studies, are running now.
Why This Gets Missed
Local treatment of metastases sits between specialties. It requires a radiation oncologist or surgeon and a medical oncologist to consider a case together, and it is not standard for every cancer type or every pattern of spread. In centres without an active multidisciplinary discussion, the option may simply not come up.
That is why it is reasonable to ask directly whether your disease could be described as oligometastatic and whether local treatment of your metastases has been considered.
Holding This Carefully
Two things are true at once. The oligometastatic concept has changed what is possible for some people with metastatic cancer, and it is a real source of hope that many patients are never told about. It also does not apply to everyone, the evidence is still maturing, and ablative treatment carries risks that depend on where the disease sits.
If you have a small number of metastases, ask whether this applies to you, ask what the goal of treatment is in plain words, and ask whether there is a clinical trial you would be eligible for. Those are three specific, answerable questions.
Sources
Words to know
Tap any term to see what it means.
Common questions
Is oligometastatic cancer curable?
For some people, yes, and that possibility is what makes the concept worth knowing about. Long-term survival and apparent cure are well documented after removing liver metastases from colorectal cancer, and after treating limited lung, adrenal or brain metastases in other cancers. But it is not the expected outcome for everyone, and durable control without cure is a more common goal. Ask your team what outcome they are aiming for in your case, in plain terms.
How many metastases is too many?
There is no fixed number. Five or fewer is the most commonly used research cut-off, but NCI is explicit that this threshold was arbitrarily decided upon. Where the metastases are, whether they can be safely reached, how quickly they appeared, and how the cancer has behaved on systemic treatment all matter as much as the count.
What is SBRT or SABR?
Stereotactic body radiation therapy, also called stereotactic ablative radiotherapy, delivers a high dose of precisely targeted radiation to a small volume over a handful of sessions. It is designed to destroy a discrete tumour while sparing surrounding tissue, and it can reach sites that would be difficult or risky to operate on.
My oncologist has not mentioned this. Should I raise it?
It is a reasonable question to ask if you have a small number of metastases. Whether it applies depends on your cancer type, where the metastases are, how well systemic treatment is working and your general fitness. Asking whether local treatment of your metastases has been considered, and whether your case has been reviewed at a multidisciplinary tumour board, is a fair and specific question.
Is this treatment risky?
It carries real risk, and it is worth being clear-eyed about that. In SABR-COMET there were three treatment-related deaths, and researchers have emphasised that treating metastases directly is not free of harm. The decision weighs the possibility of longer survival against side effects that depend heavily on where the metastases sit.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Speak With Trained Specialists & Human Navigators
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.
Help Us Improve This Guide
Did this explanation answer your question and help you determine your next step?
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Plain-language explanation of the federal sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Written by: Cancer Explained Editorial TeamSources last checked: 2026-07-30Last updated: 2026-07-30Next planned review: 2028-07-29
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source verified. This page was created with AI assistance and checked against the sources listed on it. Source checking is not a medical review.
General education. Low-risk educational or organizational content. Medical facts are cited to authoritative sources.
Human medical review: not completed. Cancer Explained is not clinician-reviewed, and that is a deliberate design choice rather than a gap we are waiting to close. We restate published federal guidance and cite it; the authority belongs to the source, not to us. That is why every page names where its claims come from — so you can verify us instead of trusting us. Use it to understand your situation and to ask better questions of the people treating you.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source verified — This page was created with AI assistance and checked against the sources listed on it. Source checking is not a medical review.
Human medical review: not completed. Cancer Explained is not clinician-reviewed, and that is a deliberate design choice rather than a gap we are waiting to close. We restate published federal guidance and cite it; the authority belongs to the source, not to us. That is why every page names where its claims come from — so you can verify us instead of trusting us. Use it to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.
Related articles
Still have questions?
Educational answers, plain language
Free to print and share